Phase 2
“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.
Yamo Pharmaceuticals, LLC announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD.
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.
Less than one year after securing a toehold in the United States, Korea-based Enzychem Lifesciences hit a major milestone with its pipeline as it eyes completion of its Phase II CRIOM (Chemoradiation Induced Oral Mucositis) study, which could lead to eventual commercialization of a treatment for the serious cancer treatment by-product.
PRESS RELEASES